Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 18:15:1456822.
doi: 10.3389/fimmu.2024.1456822. eCollection 2024.

Telitacicept in combination with B-cell depletion therapy in MuSK antibody-positive myasthenia gravis: a case report and literature review

Jia Wang #  1 , Haotao Zheng #  2 , Jia Wei #  2 , Jiaping Wu  3 , Ziyang Feng  1 , Xueqin Chen  1 , Yangsicheng Liu  1 , Wenxin Qin  1 , Xiude Qin  2 , Fanxin Kong  2
Affiliations
Review

Telitacicept in combination with B-cell depletion therapy in MuSK antibody-positive myasthenia gravis: a case report and literature review

Jia Wang et al. Front Immunol. .

Abstract

Muscle-specific kinase (MuSK) myasthenia gravis (MG) is relatively rare and has a higher incidence of myasthenic crisis compared with other subtypes. However, there is still a lack of effective treatment for refractory MuSK MG. We report the case of a 70-year-old female MuSK MG patient with recurrent fluctuations who stabilized on telitacicept in combination with anti-CD20 B-cell depletion therapy. This combination regimen deserves further investigation. Furthermore, we summarized the treatment protocols of 14 previously reported cases of MuSK MG.

Keywords: B-cell depletion therapy; case report; muscle-specific tyrosine kinase; myasthenia gravis; telitacicept.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Evolution of clinical severity of MG in the patient, assessed through QMG score and MG-ADL score. MG-ADL, myasthenia gravis specific activities of daily living scale; QMG, quantitative myasthenia gravis score.
Figure 2
Figure 2
Changes in serum immune markers in the patient. (A) changes in levels of serum IgA, IgG and IgM. (B) The changes in lymphocyte and B-cell. Laboratory reference range for Indicators: IgG: 8.60-17.40 g/L; IgA: 1.00-4.20 g/L; IgM: 0.50-2.80 g/L; CD19/lymphocyte: 5-22%; CD20/lymphocyte: 5-22%; B-cell: 5-18%.
See this image and copyright information in PMC

References

    1. Gilhus NE. Myasthenia gravis. N Engl J Med. (2016) 375:2570–81. doi: 10.1056/NEJMra1602678 - DOI - PubMed
    1. Nils E, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. (2015) 14:1023–36. doi: 10.1016/S1474-4422(15)00145-3 - DOI - PubMed
    1. Huijbers MG, Vergoossen DL, Fillié-Grijpma YE, van Es IE, Koning MT, Slot LM, et al. MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity. Neurology(R) Neuroimmunol Neuroinflammation. (2019) 6:e547. doi: 10.1212/NXI.0000000000000547 - DOI - PMC - PubMed
    1. Chaudhuri A, Behan PO. Myasthenic crisis. QJM. (2009) 102:97–107. doi: 10.1093/qjmed/hcn152 - DOI - PubMed
    1. Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discovery. (2021) 20:179–99. doi: 10.1038/s41573-020-00092-2 - DOI - PMC - PubMed

LinkOut - more resources